IRLAB continued to progress its pipeline in Q224 and met key milestones, such as the clinical entry ...
Ascelia proceeds with a rights issue of units to secure growth capital to be able to finalize and su...
Redeye returns following IRLAB's Q2 report and recent clinical progress.
Redeye leaves a note following Faron’s announcement of positive feedback from its meeting with the F...
Redeye sees that the sales beat and updated sales growth target for 2024e will excite the market.
Redeye leaves a short comment following Kancera's announcement from earlier this morning regarding c...
- We cut '24e-'26e ARR by 2-3% on continued macro weakness - Still awaiting a return in B2C business...
- We expect continued strong order intake momentum - Minor estimate changes - NTM EV/EBIT around 9x ...
Inför rapporten för det andra kvartalet som presenteras på fredag räknar Analysguiden med en tillväx...
- FTX claim sold and FlowBank investment impaired - We increase adj.
Redeye provides a research update following the Q3 report recently published by Newbury.
Redeye leaves its comments on Xspray following a press release confirming that XS003 shows matching ...
- Started IRL757 clin. development activities in Q2 - Looking for a mesdopetam Ph 3 partner - Webcas...
- Q2'24 results due 22 July - 24e-'26e EBIT revised down 1.
Det höga ränteläget fortsätter att påverka förvaltningsresultatet negativt, som sjönk med 6% på årsb...
Förvaltningsresultat ökade med 26% på årsbasis drivet av främst ränteintäkter.
Finnair reports Q2 results on Jul 19. The market still looks stable, however there have been some es...
Inför Q2-rapporten räknar Analysguiden med en liknade utvecklingen som i det första kvartalet, med a...
Redeye comments on Invisio ahead of its Q2-results (due 19 July) where we expect strong growth drive...
Redeye comments on Fantasma Games ahead of its Q2 results, due on 7 August.
